inc headquart danver
lead provid medic devic design use
primarili use either cardiac catheter
lab cath lab intervent cardiologist
heart surgeri suit cardiovascular surgeon
patient receiv devic need
prophylact hemodynam support high-risk
angioplasti procedur experienc pre-shock
shock profound cardiogen shock
reason report
price chang estim chang analysi
reiter o/v invest rate share
moder former price target per
share importantli despit fiscal shortfal
uncharacterist indic april improv sequenti versu
favor march result protect pci also
total impella secondli compani alreadi taken action
enhanc sale clinic support channel plan formal
revisit corpor guidanc follow fiscal oper period
moreov compani indic initi revenu guidanc
carri shortfal rel expect growth
forward impli baselin annual revenu guidanc rang
opinion still remain within reach
result clearli stumbl compani
remov iron throne reiter o/v invest
rate share
lower price valuat across med tech sector
broadli reset reduc former price target
per share recal former price target
assum revenu multipl approxim
revis price target assum revenu
multipl
establish conserv assum revenu
growth guidanc reflect shortfal annual fiscal
revenu growth reduc former billion
revenu earn estim million
per share respect likewis moder former
revenu earn estim billion
billion per share
guidanc rang million million impli
annual report revenu growth revenu
guidanc assum modest million contribut japan
fiscal year addit compani establish oper
margin guidanc rang
share remain notabl premium compar med tech industri
global oper margin profil support
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
addit point interest
note earn includ one-tim tax benefit fiscal
after-tax gain associ compani rate invest
fiscal oper period accordingli optic yoy earn comparison appear neg actual
appl appl earn comparison continu oper actual versu revis
earn estim per dilut share impli annual earn growth
addit earn estim reflect headwind higher assumpt
vs
fda approv compani stemi-dtu pivot trial success support regulatori approv
associ class recommend stand potenti expand annual approxim
patient unit state million patient global
still data educ end clinic bodi knowledg support stori never
better accordingli clinic econom data support use expand clinic train effort
look relat devic util acceler throughout fy
continu see potenti compani ultim deliv organ revenu growth closer
versu current guidanc rang
consolid statement incom
dollar thousand except per share data
product revenu
research develop
sell gener administr
total incom expens
fiscal period
fiscal period
incom continu oper tax
tax incom continu oper
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
